OptiBiotix Health Regulatory News (OPTI)

5 February 2016

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Placing

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing products to tackle obesity, high cholesterol and diabetes is pleased to announce that it has raised £1,000,000 (before expenses) via a placing of 1,282,051 new ordinary shares ("Placing Shares") at a price of 78 pence per share (the "Placing").

The Placing Shares have been issued to funds managed by Seneca Partners Limited ("Seneca"), a wealth manager and existing institutional investor in OptiBiotix. Following the Placing, Seneca's beneficial shareholding in the Company is 5,537,051 ordinary shares, representing 7.13 per cent. of the Company's issued share capital.

Stephen O'Hara, CEO of OptiBiotix, said: "We are delighted that Seneca, as a major shareholder and respected wealth manager, have increased their stake in OptiBiotix. The funds will be used to further accelerate our development programmes to capitalise on the growing number of opportunities arising in the rapidly evolving microbiome space and build shareholder value."

Application will be made to the London Stock Exchange to admit the Placing Shares to trading on AIM. Admission of the Placing Shares is expected to occur on or around 11 February 2016. The Placing Shares will rank pari passu with the Company's existing ordinary shares.

For the purpose of the Disclosure and Transparency Rules, following the issue of the Placing Shares, the enlarged issued share capital of the Company will comprise 77,633,976 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For further information:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.